MedTrace Logo

Use of Spectral OCT in Combination Therapy

NCT01025063 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2017-10-30

No results posted yet for this study

Summary

This study will investigate the safety and efficacy of treatment of choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) with a combination of ranibizumab (Lucentis) and verteporfin PDT (Visudyne), as compared with ranibizumab monotherapy.

Conditions

  • Choroidal Neovascularization

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Barnes Retina Institute

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-12-31
Completion
2009-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01025063 on ClinicalTrials.gov